CELLULAR KINETICS OF ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, LISOCABTAGENE MARALEUCEL (LISO-CEL) AND ITS ASSOCIATION WITH EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

被引：0
|
作者：
Nishii, R. [1 ]
Lin, H. [1 ]
Chen, W. [1 ]
Balasubramanian, N. [1 ]
Cummings, J. [1 ]
Farazi, T. [1 ]
Fasan, O. [1 ]
Vedal, M. [1 ]
Lymp, J. [1 ]
Ogasawara, K. [1 ]
机构：
[1] Bristol Myers Squibb, Summit, NJ USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2024年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-016
引用
收藏
页码：S52 / S52
页数：1
相关论文
共 50 条
  • [41] Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients
    Wang, Ying
    Li, Hujun
    Song, Xuguang
    Qi, Kunming
    Cheng, Hai
    Cao, Jiang
    Shi, Ming
    Yan, Zhiling
    Jing, Guangjun
    Pan, Bin
    Sang, Wei
    Wang, Xiangmin
    Zhao, Kai
    Chen, Chong
    Chen, Wei
    Zheng, Junnian
    Li, Zhenyu
    Xu, Kailin
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2021, 43 (02) : 250 - 258
  • [42] Incorporating radiation with anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory non-Hodgkin lymphoma: A multicenter consensus approach
    Saifi, Omran
    Lester, Scott
    Breen, William
    Rule, William
    Lin, Yi
    Bennani, N. Nora
    Rosenthal, Allison
    Munoz, Javier
    Murthy, Hemant
    Kharfan-Dabaja, Mohamed
    Peterson, Jennifer
    Hoppe, Bradford
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (01) : 124 - 134
  • [43] Cost-Effectiveness of the Chimeric Antigen Receptor (CAR) T-Cell Treatments, Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel), as Second-Line (2L) Treatment of Large B-Cell Lymphoma (LBCL)
    Lunning, Matthew
    Deger, Kristen A.
    Liu, Fei Fei
    Elsada, Ahmed
    Klijn, Sven L.
    Litkiewicz, Michal
    Franco-Villalobos, Conrado
    Sorensen, Sonja V.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S517 - S517
  • [44] TRANSFORM Study: improved Quality of Life (QOL) with Lisocabtagen maraleucel (Liso-Cel), a CD19-targeted chimeric Antigen Receptor (CAR) T-Cell Therapy, compared with Standard of Care (SOC) as Second-line Therapy (2L) in Patients (pt) with R/R large B-Cell Lymphoma (LBCL)
    Glass, B.
    Abramson, J. S.
    Johnston, P. B.
    Kamdar, M.
    Ibrahimi, S.
    Izutsu, K.
    Arnason, J.
    Mutsaers, P.
    Lunning, M.
    Braverman, J.
    Liu, F. F.
    Crotta, A.
    Montheard, S.
    Previtali, A.
    Guo, S.
    Shi, L.
    Solomon, S. R.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 255 - 256
  • [45] Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis
    Poh, Christina
    Chow, Victor A.
    Lynch, Ryan C.
    Ujjani, Chaitra S.
    Shadman, Mazyar
    Till, Brian G.
    Raghunathan, Vikram
    Warren, Edus H.
    Gauthier, Jordan
    Smith, Stephen D.
    Gujral, Taran
    Morishima, Chihiro
    Wu, Qian
    Voutsinas, Jenna M.
    Sperling, Amy
    Dizon, Joshua
    Maloney, David G.
    Gopal, Ajay K.
    BLOOD, 2023, 142
  • [46] Biomarkers of Response to Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Chronic Lymphocytic Leukemia
    Fraietta, Joseph A.
    Lacey, Simon F.
    Wilcox, Nicholas S.
    Bedoya, Felipe
    Chen, Fang
    Orlando, Elena
    Brogdon, Jennifer L.
    Hwang, Wei-Ting
    Frey, Noelle
    Young, Regina M.
    Pequignot, Edward
    Ambrose, David E.
    Levine, Bruce L.
    Bitter, Hans
    Porter, David L.
    Xu, Jun
    June, Carl H.
    Melenhorst, Jan Joseph
    BLOOD, 2016, 128 (22)
  • [47] Safety and efficacy of a novel anti-CD20 chimeric antigen receptor (CAR)-T cell therapy in relapsed/refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL) patients after failing CD19 CAR-T therapy.
    Liang, Aibin
    Ye, Shiguang
    Li, Ping
    Huang, Jiaqi
    Zhu, Shigui
    Yao, Xin
    Zhou, Lili
    Xu, Yangyang
    Zhu, Judy
    Zheng, Chengxiao
    Chen, Shiyi
    Lan, Liping
    Lv, Xiaoteng
    Wei, Yutian
    Humphries, Michael
    Yao, Yihong
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [48] Efficacy of anti-CD19 chimeric antigen receptor modified T(CAR-T) cell therapy in Chinese patients with relapsed/refractory acute lymphocytic leukemia in a multicenter trial.
    Xiao, Lei
    Huang, He
    Huang, Xiaojun
    Ke, Xiaoyan
    Hu, Yu
    Li, Junmin
    Zhang, Qing
    Hu, Yongxian
    Jiang, Qian
    Hu, Jiang
    Jing, Hongmei
    Zhang, Xiaohong
    Wu, Zhao
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [49] Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients ( Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study
    Kamdar, Manali
    Solomon, Scott R.
    Arnason, Jon E.
    Johnston, Patrick B.
    Glass, Bertram
    Bachanova, Veronika
    Ibrahimi, Sami
    Mielke, Stephan
    Mutsaers, Pim G. N. J.
    Hernandez-Ilizaliturri, Francisco J.
    Izutsu, Koji
    Morschhauser, Franck
    Lunning, Matthew A.
    Maloney, David G.
    Crotta, Alessandro
    Montheard, Sandrine
    Previtali, Alessandro
    Stepan, Lara
    Ogasawara, Ken
    Mack, Timothy
    Abramson, Jeremy S.
    BLOOD, 2021, 138
  • [50] Evaluation of the safety and efficacy of humanized anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma based on the comprehensive geriatric assessment system
    Zhang, Huan
    Liu, Man
    Li, Qing
    Lyu, Cuicui
    Jiang, Yan-Yu
    Meng, Juan-Xia
    Li, Jing-Yi
    Deng, Qi
    LEUKEMIA & LYMPHOMA, 2022, 63 (02) : 353 - 361
12345